Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SetPoint Raises $140M to Support Neuromod RA Therapy
Financial/Business, OEM News

SetPoint Raises $140M to Support Neuromod RA Therapy Commercialization

The company’s neuroimmune platform won FDA approval for rheumatoid arthritis (RA) late last month.

The SetPoint System. Photo: SetPoint Medical.

SetPoint Medical has raised $140 million in private financing, which includes $25 million in the second tranche of its Series C financing, and $115 million in its Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group.

The company said these proceeds will support commercialization of the SetPoint system, a neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis (RA). It will also be used to advance the company’s pipeline in other autoimmune conditions.

In conjunction with the Series D, Josh Makower, MD joined the company’s board of directors as a representative of Elevage Medical Technologies, along with Kevin Reilly, Managing Director and Head of MedTech investments at Ally Bridge Group.

SetPoint also made two new executive appointments. Erik Styacich, former VP of Sales for neuromodulation company Valencia Technologies, joined as VP of Sales, and Spencer Bailey joined as VP of Market Access & Reimbursement, after holding several similar leadership roles at other neuromodulation companies, including MicroTransponder.

The company’s neuroimmune platform won FDA approval for RA late last month.

“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026,” said Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters